AGENUS INC Finance Lease, Liability, to be Paid, Year Four
AGENUS INC (AGEN) had Finance Lease, Liability, to be Paid, Year Four of $0 as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour · last filed 2026-03-16
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Four $0.00.
- 2024-12-31: Finance Lease, Liability, to be Paid, Year Four $0.00.
- 2023-12-31: Finance Lease, Liability, to be Paid, Year Four $0.00.
| Period end | Finance Lease, Liability, to be Paid, Year Four |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-17 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |